A lower risk of cardiac arrest (OR: 0.415, 95% CI: 0.381–0.451), acute HF (OR: 0.723, 95% CI: 0.696–0.751), and cardiogenic shock (OR: 0.528, 95% CI: 0.485–0.575) were also observed in GLP-1 agonist user cohort during the 3-year follow-up duration. Here, GLP1R is linked to cardiac arrest.